用加权多基因药基因组测试对抑郁症成人的反应和缓解结果的元分析
Renee E Albers1, Melissa P Dyer1, Matthew Kucera1
1Myriad Genetics, Inc., Salt Lake City, UT.
Journal of clinical psychopharmacology
|September 3, 2025
概括
药物基因组 (PGx) 测试显著改善了严重抑郁症患者的治疗结果. 这种加权的多基因PGx测试引导治疗导致先前治疗失败的成年人反应和缓解率更高.
科学领域:
- 药物基因组学
- 精神病学
- 临床遗传学
背景情况:
- 之前对主要抑郁症 (MDD) 的药基因组测试进行的分析,由于测试和设计不同,结果不确定.
- 需要评估标准化,加权的多基因PGx测试对MDD治疗的临床效用.
研究的目的:
- 在患有MDD的成年患者中评估单重多基因PGx测试的临床效用.
- 使用指导治疗的特定PGx测试进行前性研究的元分析.
主要方法:
- 在主要数据库 (MEDLINE/PubMed,Cochrane,Embase,clinicaltrials.gov,ICTRP) 进行了系统的文献搜索,截至2025年5月.
- 按照PRISMA的指导方针,确定并包括6项前性研究,比较成人MDD患者的PGx指导护理和非指导护理,使用加权的多基因测试.
- 总共有3532名患者被纳入了分析.
主要成果:
- 接受多基因PGx测试指导的患者获得反应的可能性增加了30% (RR=1.30,P<0.001).
- 与未指导治疗相比,PGx指导治疗组的缓解率是41%高 (RR=1. 41,P< 0. 001).
- 在包括的研究中没有显著的异质性.
结论:
- 在至少一次先前治疗失败的成年MDD患者中,加权的多基因PGx测试显著提高了反应和缓解率.
- 这些发现证实了这种特定PGx测试方法在优化MDD治疗方面的临床效用和有效性.
相关概念视频
Antidepressant Drugs: MAOIs and Other Agents
340
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
340
Human Genetics
716
Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
The complex relationship between genetics and psychology is observable through common biological components such...
716
Factors Affecting Drug Response: Overview
2.4K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.4K


